Group 1 - The company, Heartbeat Company (02400), announced a share buyback on January 16, 2026, spending HKD 1.9731 million to repurchase 23,200 shares at a price range of HKD 83.45 to 86.15 per share [1] - On the same date, the company issued a total of 33,000 ordinary shares due to eligible participants exercising stock options under the share option scheme adopted on June 25, 2021 [1]

Core Viewpoint - The company Tian Sheng New Materials plans to raise no more than 253 million yuan through a private placement of shares, with the net proceeds intended for repaying bank loans and/or supplementing working capital [1] Group 1: Fundraising Details - The company will issue shares to a specific entity, Beijing Rongsheng Zhizhi Technology Development Partnership (Limited Partnership) [1] - The issue price is set at 5.06 yuan per share, with a total of 50 million shares to be subscribed [1] - After the issuance, the controlling shareholder will change to Beijing Rongsheng Zhizhi Technology Development Partnership (Limited Partnership) [1] Group 2: Ownership Changes - Prior to the issuance, the company had no controlling shareholder or actual controller [1] - Following the issuance, the actual controller will change to Wei Lidong [1]

Core Viewpoint - Shandong Pharmaceutical Glass Co., Ltd. plans to issue up to 199,084,233 A-shares at a price of 16.25 yuan per share, aiming to raise no more than 3.235 billion yuan to supplement working capital, with a change in control to China National Pharmaceutical Group Corporation [2][4][6] Trading Information Summary - As of January 14, 2026, Shandong Pharmaceutical Glass closed at 21.0 yuan, up 2.24%, with a turnover rate of 4.63%, trading volume of 307,500 shares, and a transaction amount of 645 million yuan [1] - On the same day, the net inflow of main funds was 9.6426 million yuan, accounting for 1.5% of the total transaction amount, while retail investors had a net outflow of 1.5527 million yuan, accounting for 0.24% [2] Company Announcement Summary - The company’s board approved a proposal to issue shares to specific entities, which requires further approval from the shareholders' meeting, state-owned asset regulatory authorities, the Shanghai Stock Exchange, and the China Securities Regulatory Commission [2][4] - The issuance will result in a change of control, with China National Pharmaceutical Group becoming the actual controller, and the original controlling shareholder, Luzhong Investment, terminating its cooperation with China National Pharmaceutical International on January 11, 2026 [3][6] - The company has committed not to provide financial assistance or guarantees to the issuing entities and has acknowledged the potential dilution of immediate returns from this issuance [4][5] Financial and Operational Insights - The company’s previous fundraising net amount was approximately 1.842 billion yuan, with 1.141 billion yuan invested by September 30, 2025, and the investment progress is reported as normal [4][5] - The company expects to have daily related transactions with China National Pharmaceutical Group totaling 46.7 million yuan in 2026, primarily for the sale of pharmaceutical glass packaging materials [5] - The feasibility analysis report indicates that the raised funds will be used entirely to supplement working capital, enhancing capital strength, research innovation capabilities, and risk resistance [5][6]

Group 1 - Morgan Stanley's Asia revenue approached a record $10 billion last year, leading to a 20% increase in the overall bonus pool for local bankers [1] - The revenue surge was primarily driven by strong performances in equity trading, institutional brokerage, and wealth management, with investment banking and capital markets also regaining growth momentum [1] - The investment banking department saw bonuses increase by 15% to 20%, with top performers in the institutional equity division receiving bonuses of at least 30% [1] Group 2 - In 2024, Morgan Stanley's Asia revenue was $7.64 billion, accounting for 12% of the group's global total, marking the third consecutive year of outperforming Goldman Sachs in the region [2] - The Asia-Pacific business, including Japan and Australia, experienced a 29% revenue growth to $7.27 billion in the nine months ending September last year, reflecting a strong performance amid market volatility [2] - Despite record performance in Asia, the company remains cautious about significantly increasing bonuses to smooth out compensation expenses, influenced by stock price increases and a large junior employee base [2]

Core Viewpoint - China National Airlines (601111) has received a notification from the Shanghai Stock Exchange regarding the acceptance of its application for issuing securities on the Shanghai main board [1] Group 1: Application Process - The Shanghai Stock Exchange has reviewed the company's submitted prospectus and related application documents, finding them complete and in legal form, thus deciding to accept the application for review [1] - The issuance of A-shares to specific investors still requires approval from the Shanghai Stock Exchange and registration with the China Securities Regulatory Commission (CSRC) [1] Group 2: Uncertainties and Compliance - There are uncertainties regarding whether the company will obtain approval from the Shanghai Stock Exchange and the CSRC, as well as the timeline for these approvals [1] - The company will fulfill its information disclosure obligations in accordance with relevant laws and regulations regarding the issuance of A-shares to specific investors based on the progress of the application [1]

Core Viewpoint - The company has adjusted its plan for issuing shares to specific investors, aiming to raise a total of no more than 227 million yuan, which will not exceed 30% of the company's total share capital before the issuance [1] Fund Utilization - The raised funds will be allocated to the construction of a boar station, a breeding technology research base, digital intelligence construction projects, and to supplement working capital [1] Purpose of Adjustment - The adjustment is intended to optimize the efficiency of fund utilization and enhance the effectiveness of project implementation [1]

Group 1 - The core point of the news is that Shenzhen Magpower Electric Co., Ltd. plans to issue shares to specific investors to raise up to 2.663 billion yuan for various expansion projects and working capital [1][3] - The company has received approval from the China Securities Regulatory Commission (CSRC) for the share issuance, which is valid for 12 months from the date of approval [1][2] - The expected annual revenue increase from the projects after reaching production is estimated to be 6.033 billion yuan [1][3] Group 2 - On January 5, 2026, the company's stock closed at 91.03 yuan, with a trading volume of 172,500 shares and a turnover of 1.56 billion yuan [1] - The main funds saw a net inflow of 32.962 million yuan, indicating a positive short-term attitude from major investors [3] - The board of directors authorized the chairman to adjust the issuance price based on bidding conditions to ensure that at least 70% of the planned shares are issued [2]

Group 1 - The core viewpoint of the article is that International Medical has clarified its fundraising plan for the 2025 fiscal year, which will be used for specific projects and working capital [1] - The funds raised will be allocated to the Smart Health and Elderly Care Project, the Phase II Proton Therapy Center Project, and to supplement working capital [1] - The company emphasizes that the fundraising is compliant and does not involve any acquisition matters [1] Group 2 - The company assures that it strictly adheres to laws, regulations, and regulatory requirements to ensure proper corporate governance [1] - All significant matters will be disclosed in accordance with information disclosure rules in a timely manner [1] - For any external investments or asset acquisitions, the company advises stakeholders to refer to formal announcements published in designated information disclosure media [1]

Core Viewpoint - Shaanxi Tourism Culture Industry Co., Ltd. has received approval for its initial public offering (IPO) of A-shares, with a determined price of 80.44 yuan per share [1] Group 1: IPO Details - The total number of shares issued is 19,333,334, accounting for 25% of the company's total share capital post-issue, with a total share capital of 77,333,334 shares [2] - All shares are publicly issued new shares, with no existing shareholders selling shares in this offering [2] - The online issuance accounts for 99.9983% of the total issuance, with the underwriter covering the remaining shares that did not meet the minimum subscription unit [2] Group 2: Subscription and Underwriting - The online subscription period ended on December 24, 2025, with a total of 19,117,061 shares subscribed by online investors [3] - The underwriter has committed to cover 216,273 shares, which represents 1.12% of the total issuance [3][4] - The total amount raised from online investors is approximately 1.54 billion yuan [4] Group 3: Issuance Costs - The total issuance costs amount to 33.25 million yuan, broken down into various fees including underwriting, auditing, and legal fees [5] - Underwriting fees are set at 21 million yuan, while auditing and legal fees are 2.27 million yuan and 1.51 million yuan respectively [5]

经公司向深圳证券交易所申请，公司股票自2025年12月25日(星期四)上午开市起复牌。 智通财经APP讯，联创电子(002036.SZ)发布公告，2025年12月24日，江西鑫盛与南昌市北源智能产业投 资合伙企业(有限合伙)(以下简称"北源智能")签署了《江西鑫盛投资有限公司与南昌市北源智能产业投 资合伙企业(有限合伙)关于联创电子科技股份有限公司之股份转让协议》，约定北源智能分批支付9亿 元收购江西鑫盛持有的联创电子无限售流通股7086.61万股，占公司股份总数的6.71%。 2025年12月24日，公司与江西国资创投签订了《附条件生效的股份认购协议》，江西国资创投拟通过现 金方式认购上市公司向特定对象发行的不超过1.89亿股股票。本次发行完成后，在不考虑其他因素可能 导致股本数量变动的情况下，按照拟发行股数上限计算，江西国资创投将直接持有公司股份1.89亿股， 占发行后上市公司股份总数的15.19%。上述协议转让和股票发行完成后，江西国资创投直接和间接持 有公司股份占发行后上市公司股份总数的20.89%。 上述协议转让完成后，公司控股股东变更为北源智能，江西国资创投为公司的间接控股股东，公司实际 控制人将 ...